◎ Sugi Atlas

Atlas / Gene / OPLAH

OPLAH

gene
On this page

Also known as OPLA5-Opase

Summary

OPLAH (5-oxoprolinase, ATP-hydrolysing, HGNC:8149) is a protein-coding gene on chromosome 8q24.3, encoding 5-oxoprolinase (O14841). Catalyzes the cleavage of 5-oxo-L-proline to form L-glutamate coupled to the hydrolysis of ATP to ADP and inorganic phosphate.

The protein encoded by this gene acts as a homodimer, using ATP hydrolysis to catalyze the conversion of 5-oxo-L-proline to L-glutamate. Defects in this gene are a cause of 5-oxoprolinase deficiency (OPLAHD).

Source: NCBI Gene 26873 — RefSeq curated summary.

At a glance

  • Gene–disease (curated): 5-oxoprolinase deficiency (Strong, GenCC)
  • GWAS associations: 8
  • Clinical variants (ClinVar): 640 total — 21 pathogenic, 23 likely-pathogenic
  • Phenotypes (HPO): 26
  • MANE Select transcript: NM_017570

Identifiers

Gene identifiers

FieldValue
HGNC IDHGNC:8149
Approved symbolOPLAH
Name5-oxoprolinase, ATP-hydrolysing
Location8q24.3
Locus typegene with protein product
StatusApproved
AliasesOPLA, 5-Opase
Ensembl geneENSG00000178814
Ensembl biotypeprotein_coding
OMIM614243
Entrez26873

Gene structure

Transcript identifiers

Ensembl transcripts: 34 — 32 protein_coding, 2 retained_intron

ENST00000527993, ENST00000531027, ENST00000567871, ENST00000618853, ENST00000894953, ENST00000894954, ENST00000894955, ENST00000894956, ENST00000894957, ENST00000894958, ENST00000894959, ENST00000894960, ENST00000894961, ENST00000894962, ENST00000894963, ENST00000894964, ENST00000894965, ENST00000894966, ENST00000919620, ENST00000971668, ENST00000971669, ENST00000971670, ENST00000971671, ENST00000971672, ENST00000971673, ENST00000971674, ENST00000971675, ENST00000971676, ENST00000971677, ENST00000971678, ENST00000971679, ENST00000971680, ENST00000971681, ENST00000971682

RefSeq mRNA: 1 — MANE Select: NM_017570 NM_017570

CCDS: CCDS75802

Canonical transcript exons

ENST00000618853 — 27 exons

ExonStartEnd
ENSE00002601182144058773144058896
ENSE00002613541144058496144058691
ENSE00002616323144058239144058404
ENSE00003489696144058980144059079
ENSE00003546594144059599144059790
ENSE00003624579144059862144060085
ENSE00003714833144052983144053129
ENSE00003715520144051729144051826
ENSE00003718139144051916144052076
ENSE00003720937144054812144054913
ENSE00003721768144055788144055939
ENSE00003725858144054561144054735
ENSE00003730193144060653144060692
ENSE00003730662144053209144053393
ENSE00003731328144052169144052326
ENSE00003733209144056948144057118
ENSE00003733719144051266144051472
ENSE00003739282144058010144058148
ENSE00003740140144057856144057923
ENSE00003740799144055029144055189
ENSE00003741166144052449144052598
ENSE00003741275144056147144056259
ENSE00003742414144057208144057320
ENSE00003742542144056618144056755
ENSE00003744508144052766144052900
ENSE00003745488144056385144056523
ENSE00003748898144057448144057713

Expression profiles

Bgee: expression breadth ubiquitous, 217 present calls, max score 96.67.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 7.6594 / max 219.5208, expressed in 1369 samples.

FANTOM5 promoters (6 alternative TSS)

Promoter IDTPM avgSamples expressed
956045.09681058
956051.6259796
956060.7088317
956090.12056
956080.094851
956100.01264

Top tissues by expression

275 total, by Bgee expression score (0-100, higher = more expressed):

TissueAnatomy IDExpression scoreQuality
apex of heartUBERON:000209896.67gold quality
right testisUBERON:000453494.49gold quality
left testisUBERON:000453394.35gold quality
right atrium auricular regionUBERON:000663193.68gold quality
right lobe of liverUBERON:000111491.53gold quality
cardiac atriumUBERON:000208191.43gold quality
gastrocnemiusUBERON:000138891.40gold quality
hindlimb stylopod muscleUBERON:000425291.21gold quality
testisUBERON:000047391.03gold quality
heart left ventricleUBERON:000208490.66gold quality
cardiac ventricleUBERON:000208290.06gold quality
muscle of legUBERON:000138389.69gold quality
body of stomachUBERON:000116188.80gold quality
transverse colonUBERON:000115787.90gold quality
mucosa of transverse colonUBERON:000499187.90gold quality
right adrenal gland cortexUBERON:003582787.28gold quality
metanephros cortexUBERON:001053387.20gold quality
heartUBERON:000094886.98gold quality
right adrenal glandUBERON:000123386.66gold quality
left adrenal gland cortexUBERON:003582586.15gold quality
left adrenal glandUBERON:000123486.08gold quality
esophagus mucosaUBERON:000246985.41gold quality
lower esophagus mucosaUBERON:003583485.09gold quality
skin of abdomenUBERON:000141685.04gold quality
adrenal cortexUBERON:000123584.87gold quality
muscle organUBERON:000163084.79gold quality
small intestine Peyer’s patchUBERON:000345484.41gold quality
minor salivary glandUBERON:000183083.79gold quality
esophagusUBERON:000104383.56gold quality
stomachUBERON:000094583.24gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

ExperimentMarker?Max mean expression
E-ANND-3yes3.10

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 3)

  • the cause of cellular ATP depletion in nephrotic cystinosis may be the futile cycle, formed between two ATP-dependant gamma-glutamyl cycle enzymes, gamma-glutamyl cysteine synthetase and 5-oxoprolinase (PMID:20413906)
  • In this study, clinical, biochemical, and genetic aspects of five Chinese 5-oxoprolinuria patients with OPLAH or GSS gene mutations were investigated. (PMID:25851806)
  • An autosomal recessive mode of inheritance for 5-oxoprolinase deficiency is further supported by the identification of a single mutation in all 9/14 parent sample sets investigated (except for the father of one patient whose result suggests homozygosity), and the absence of 5-oxoprolinuria in all tested heterozygotes (PMID:27477828)

Cross-species orthologs

5 orthologs

OrganismSymbolGene ID
danio_reriooplahENSDARG00000045123
mus_musculusOplahENSMUSG00000022562
rattus_norvegicusOplahENSRNOG00000011781
drosophila_melanogasterCG4752FBGN0034733
caenorhabditis_elegansWBGENE00021430

Protein

Protein identifiers

5-oxoprolinase — O14841 (reviewed: O14841)

Alternative names: 5-oxo-L-prolinase, Pyroglutamase

All UniProt accessions (2): O14841, A0A087WY99

UniProt curated annotations — full annotation on UniProt →

Function. Catalyzes the cleavage of 5-oxo-L-proline to form L-glutamate coupled to the hydrolysis of ATP to ADP and inorganic phosphate.

Subunit / interactions. Homodimer.

Subcellular location. Cytoplasm. Cytosol.

Disease relevance. 5-oxoprolinase deficiency (OPLAHD) [MIM:260005] A disorder characterized by calcium oxalate/carbonate urolithiasis, and excessive urinary 5-oxo-L-proline. Affected individuals have recurrent episodes of vomiting, diarrhea, and abdominal pain. The disease is caused by variants affecting the gene represented in this entry.

Similarity. Belongs to the oxoprolinase family.

RefSeq proteins (1): NP_060040* (*=MANE)

Domains & families (InterPro)

IDNameType
IPR002821Hydantoinase_ADomain
IPR003692Hydantoinase_BDomain
IPR008040Hydant_A_NDomain
IPR045079Oxoprolinase-likeFamily
IPR049517ACX-like_CDomain

Pfam: PF01968, PF02538, PF05378, PF19278

Enzyme classification (BRENDA):

  • EC 3.5.2.9 — 5-oxoprolinase (ATP-hydrolysing) (BRENDA: 29 organisms, 51 substrates, 21 inhibitors, 39 Km, 1 kcat entries)

Substrate kinetics (BRENDA)

9 substrates with measured Km, best-characterized 9. Km ranges are aggregated across organisms/conditions.

SubstrateKm (mM)Measurements
5-OXOPROLINE0.0316–0.5812
ATP0.03–18
5-OXO-L-PROLINE0.005–0.05116
ITP0.13–0.414
MGATP2-0.1–4.24
UTP0.17–1.112
L-2-OXOTHIAZOLIDINE-4-CARBOXYLATE0.171
L-2-OXOTHIAZOLIDINE-4-CARBOXYLIC ACID0.0021
MNATP2-0.51

Catalyzed reactions (Rhea), 1 shown:

  • 5-oxo-L-proline + ATP + 2 H2O = L-glutamate + ADP + phosphate + H(+) (RHEA:10348)

UniProt features (8 total): sequence variant 3, modified residue 2, chain 1, region of interest 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

ModelpLDDTFraction very-high
AF-O14841-F188.080.58

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (2): 151, 1265

Function

Pathways and Gene Ontology

Reactome pathways

2 pathways

IDPathway
R-HSA-174403Glutathione synthesis and recycling
R-HSA-5578998Defective OPLAH causes OPLAHD

MSigDB gene sets: 184 (showing top): REACTOME_BIOLOGICAL_OXIDATIONS, MORF_MSH3, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_UP, GRAESSMANN_RESPONSE_TO_MC_AND_DOXORUBICIN_UP, KANG_FLUOROURACIL_RESISTANCE_DN, GOBP_AMIDE_METABOLIC_PROCESS, REACTOME_GLUTATHIONE_CONJUGATION, GOBP_GLUTATHIONE_METABOLIC_PROCESS, GOBP_MODIFIED_AMINO_ACID_METABOLIC_PROCESS, MORF_PRKACA, MARSON_BOUND_BY_FOXP3_UNSTIMULATED, SANSOM_APC_MYC_TARGETS, MORF_KDR, NIKOLSKY_BREAST_CANCER_8Q23_Q24_AMPLICON, KEGG_GLUTATHIONE_METABOLISM

GO Biological Process (1): glutathione metabolic process (GO:0006749)

GO Molecular Function (7): ATP binding (GO:0005524), 5-oxoprolinase (ATP-hydrolyzing) activity (GO:0017168), identical protein binding (GO:0042802), nucleotide binding (GO:0000166), catalytic activity (GO:0003824), protein binding (GO:0005515), hydrolase activity (GO:0016787)

GO Cellular Component (2): cytosol (GO:0005829), cytoplasm (GO:0005737)

Reactome top-level categories

Rollup of top-2 pathways:

CategoryPathways
Glutathione conjugation1
Metabolic disorders of biological oxidation enzymes1

GO top-level categories

Rollup of top GO terms by namespace:

CategoryTerms
cellular anatomical structure2
modified amino acid metabolic process1
sulfur compound metabolic process1
adenyl ribonucleotide binding1
purine ribonucleoside triphosphate binding1
hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds, in cyclic amides1
protein binding1
nucleoside phosphate binding1
heterocyclic compound binding1
molecular_function1
binding1
catalytic activity1
cytoplasm1
intracellular anatomical structure1

Protein interactions and networks

STRING

1168 interactions, top by confidence (×1000):

Protein AProtein BPartner UniProtScore
OPLAHGGCTO75223629
OPLAHMGST3O14880567
OPLAHGSSP48637522
OPLAHGGT5P36269490
OPLAHTMEM276P0DTL5454
OPLAHCNDP2Q96KP4437
OPLAHAP4S1Q9Y587428
OPLAHKYAT3Q6YP21427
OPLAHZNF610Q8N9Z0417
OPLAHSUOXP51687411
OPLAHL3HYPDHQ96EM0410
OPLAHNAGKQ9UJ70410
OPLAHPACS1Q6VY07402
OPLAHKCNC3Q14003391
OPLAHLRRC24Q50LG9390

IntAct

22 interactions, top by confidence:

ABTypeScore
OPLAHPOU6F2psi-mi:“MI:0915”(physical association)0.560
OPLAHOPLAHpsi-mi:“MI:0915”(physical association)0.560
OPLAHpsi-mi:“MI:0915”(physical association)0.560
OPLAHTPK1psi-mi:“MI:0915”(physical association)0.560
OPLAHHOXA1psi-mi:“MI:0915”(physical association)0.370
GKOPLAHpsi-mi:“MI:0915”(physical association)0.370
NUDCD1DNAJB2psi-mi:“MI:0914”(association)0.350
MAPTSHTN1psi-mi:“MI:0914”(association)0.350
PTGES2COX7A2Lpsi-mi:“MI:0914”(association)0.350
CEBPASAP18psi-mi:“MI:0914”(association)0.350
ESYT2psi-mi:“MI:0914”(association)0.350
OPLAHPOU6F2psi-mi:“MI:0915”(physical association)0.000
OPLAHOPLAHpsi-mi:“MI:0915”(physical association)0.000
OPLAHpsi-mi:“MI:0915”(physical association)0.000
OPLAHTPK1psi-mi:“MI:0915”(physical association)0.000

BioGRID (14): OPLAH (Affinity Capture-MS), OPLAH (Affinity Capture-MS), OPLAH (Affinity Capture-MS), OPLAH (Two-hybrid), OPLAH (Two-hybrid), OPLAH (Two-hybrid), TPK1 (Two-hybrid), OPLAH (Two-hybrid), OPLAH (Affinity Capture-MS), OPLAH (Affinity Capture-MS), OPLAH (Affinity Capture-MS), OPLAH (Affinity Capture-MS), OPLAH (Reconstituted Complex), OPLAH (Two-hybrid)

ESM2 similar proteins: A0LIN6, A1ANJ7, A1VD24, A1VF55, A2C7G2, A2CCB6, A5GIK5, A5GMV4, A5GW48, A5W7G2, B0KTX5, B1J5G5, B2GKK6, B5EQG3, B5FSZ0, B5XP95, B7JAG8, B8J025, C1D0A9, O14841, O15067, P27708, P97608, Q10093, Q10094, Q1I447, Q2JJA1, Q2JKQ8, Q2JLQ2, Q30WM4, Q30ZN1, Q39YF3, Q3AMW4, Q50899, Q5FNS3, Q5HZE4, Q5P5G2, Q72B00, Q72DJ9, Q75WB5

Diamond homologs: O14841, P28273, P97608, Q01262, Q10093, Q10094, Q54NW6, Q58373, Q75WB5, Q8K010, Q9FIZ7, W3X7R6, A0A2W0EVE0, Q58374, Q5P5G4, Q01263

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

640 variants total. Per-class counts are floors (≥ shown; pagination cap):

ClassificationCount (floor)
Pathogenic21
Likely pathogenic23
Uncertain significance318
Likely benign189
Benign44

Top pathogenic / likely-pathogenic (30)

Variant IDHGVSClassification
1179038NM_017570.5(OPLAH):c.313_316del (p.Arg105fs)Pathogenic
1179092NM_017570.5(OPLAH):c.2076C>A (p.Cys692Ter)Pathogenic
2037024NM_017570.5(OPLAH):c.206_251dup (p.Thr85fs)Pathogenic
2194554NM_017570.5(OPLAH):c.3612C>G (p.Tyr1204Ter)Pathogenic
2770865NM_017570.5(OPLAH):c.2677C>T (p.Gln893Ter)Pathogenic
2776954NM_017570.5(OPLAH):c.2362dup (p.His788fs)Pathogenic
2835035NM_017570.5(OPLAH):c.1652del (p.Leu551fs)Pathogenic
2870863NM_017570.5(OPLAH):c.2669del (p.Gly890fs)Pathogenic
3017064NM_017570.5(OPLAH):c.3249_3250delinsTT (p.Gln1084Ter)Pathogenic
31133NM_017570.5(OPLAH):c.2608dup (p.His870fs)Pathogenic
3600351NM_017570.5(OPLAH):c.3081dup (p.Arg1028fs)Pathogenic
3600352NM_017570.5(OPLAH):c.3701C>A (p.Ser1234Ter)Pathogenic
3607909NM_017570.5(OPLAH):c.3457_3458del (p.Ser1153fs)Pathogenic
3670809NM_017570.5(OPLAH):c.3187C>T (p.Arg1063Ter)Pathogenic
39635NM_017570.5(OPLAH):c.969C>A (p.Ser323Arg)Pathogenic
4716570NM_017570.5(OPLAH):c.975del (p.Arg324_Tyr325insTer)Pathogenic
4733188NM_017570.5(OPLAH):c.1336_1337del (p.Ser446fs)Pathogenic
504164NM_017570.5(OPLAH):c.587+1G>CPathogenic
572337NM_017570.5(OPLAH):c.2557C>T (p.Arg853Ter)Pathogenic
856398NM_017570.5(OPLAH):c.493C>T (p.Gln165Ter)Pathogenic
955289NM_017570.5(OPLAH):c.2987dup (p.Arg997fs)Pathogenic
1324831NM_017570.5(OPLAH):c.893C>G (p.Ser298Ter)Likely pathogenic
191344NM_017570.5(OPLAH):c.2303G>A (p.Arg768His)Likely pathogenic
2432374NM_017570.5(OPLAH):c.3019-2A>GLikely pathogenic
2628865NM_017570.5(OPLAH):c.3259del (p.Val1087fs)Likely pathogenic
2690662NM_017570.5(OPLAH):c.169C>T (p.Gln57Ter)Likely pathogenic
2690663NM_017570.5(OPLAH):c.2686+1G>TLikely pathogenic
3052754NM_017570.5(OPLAH):c.2848C>T (p.Gln950Ter)Likely pathogenic
3254835NM_017570.5(OPLAH):c.3394G>T (p.Gly1132Trp)Likely pathogenic
3355213NM_017570.5(OPLAH):c.3795_3796insACCCCGCCCCACCGCCGGTGTCG (p.Pro1266fs)Likely pathogenic

SpliceAI

3806 predictions. Top by Δscore:

VariantEffectΔscore
8:144051724:CTTA:Cdonor_loss1.0000
8:144051725:TTA:Tdonor_loss1.0000
8:144051726:TACCC:Tdonor_loss1.0000
8:144051727:A:ACdonor_gain1.0000
8:144051727:AC:Adonor_gain1.0000
8:144051727:ACC:Adonor_gain1.0000
8:144051728:C:CCdonor_gain1.0000
8:144051728:CC:Cdonor_gain1.0000
8:144051728:CCC:Cdonor_gain1.0000
8:144051738:CACGG:Cdonor_gain1.0000
8:144051740:CGG:Cdonor_gain1.0000
8:144051928:ATGG:Adonor_gain1.0000
8:144051972:T:TAdonor_gain1.0000
8:144052073:GTACC:Gacceptor_loss1.0000
8:144052076:CCTGC:Cacceptor_loss1.0000
8:144052086:C:CTacceptor_gain1.0000
8:144052163:GCTCA:Gdonor_loss1.0000
8:144052164:CTCAC:Cdonor_loss1.0000
8:144052165:TCACC:Tdonor_loss1.0000
8:144052166:CACCG:Cdonor_loss1.0000
8:144052167:A:ACdonor_gain1.0000
8:144052167:A:Cdonor_loss1.0000
8:144052168:C:CAdonor_loss1.0000
8:144052168:C:CCdonor_gain1.0000
8:144052168:CCGG:Cdonor_gain1.0000
8:144052761:CGAA:Cdonor_loss1.0000
8:144052763:AACC:Adonor_loss1.0000
8:144052765:C:CGdonor_loss1.0000
8:144052896:CTGCC:Cacceptor_gain1.0000
8:144052899:CC:Cacceptor_gain1.0000

AlphaMissense

8282 scored. Top likely-pathogenic:

VariantProtein changeam_pathogenicity
8:144054684:G:CH855D0.999
8:144054863:G:CN820K0.999
8:144054863:G:TN820K0.999
8:144055125:G:CF771L0.999
8:144055125:G:TF771L0.999
8:144055127:A:GF771L0.999
8:144055128:G:CD770E0.999
8:144055128:G:TD770E0.999
8:144055129:T:AD770V0.999
8:144055140:C:AK766N0.999
8:144055140:C:GK766N0.999
8:144053283:C:GG933R0.998
8:144053312:A:GL923P0.998
8:144054841:G:CH828D0.998
8:144054842:G:CS827R0.998
8:144054842:G:TS827R0.998
8:144054844:T:GS827R0.998
8:144055064:G:CH792D0.998
8:144055119:A:CC773W0.998
8:144055123:G:AS772F0.998
8:144055129:T:CD770G0.998
8:144055129:T:GD770A0.998
8:144055146:G:CN764K0.998
8:144055146:G:TN764K0.998
8:144055160:C:GA760P0.998
8:144055181:C:GG753R0.998
8:144056502:A:CF622L0.998
8:144056502:A:TF622L0.998
8:144056504:A:GF622L0.998
8:144056508:A:CF620L0.998

dbSNP variants (sampled 300 via entrez): RS1000846332 (8:144060753 C>T), RS1000898676 (8:144060530 C>T), RS1001007560 (8:144065654 G>A), RS1001360197 (8:144056067 C>T), RS1001510912 (8:144063089 C>T), RS1001561867 (8:144062892 C>A,G,T), RS1002525489 (8:144050469 A>G), RS1002641564 (8:144050709 G>A,C,T), RS1003171747 (8:144063988 G>A), RS1003224197 (8:144063839 C>G), RS1004147172 (8:144059168 T>G), RS1004197947 (8:144051637 C>T), RS1004312478 (8:144051893 G>A), RS1004921190 (8:144060074 G>A,T), RS1005115217 (8:144064604 A>G)

Disease associations

OMIM: gene MIM:614243 | disease phenotypes: MIM:260005, MIM:600513

GenCC curated gene-disease

DiseaseClassificationInheritance
5-oxoprolinase deficiencyStrongAutosomal recessive

Mondo (2): 5-oxoprolinase deficiency (MONDO:0009825), familial sleep-related hypermotor epilepsy (MONDO:0000030)

Orphanet (2): 5-oxoprolinase deficiency (Orphanet:33572), Sleep-related hypermotor epilepsy (Orphanet:98784)

HPO phenotypes

26 total (26 of 26 shown, HPO-id order):

HPOTerm
HP:0000006Autosomal dominant inheritance
HP:0000007Autosomal recessive inheritance
HP:0000252Microcephaly
HP:0000486Strabismus
HP:0000750Delayed speech and language development
HP:0000787Nephrolithiasis
HP:0000952Jaundice
HP:0001250Seizure
HP:0001252Hypotonia
HP:0001262Excessive daytime somnolence
HP:0001263Global developmental delay
HP:0001508Failure to thrive
HP:0001942Metabolic acidosis
HP:0001943Hypoglycemia
HP:0002013Vomiting
HP:0002014Diarrhea
HP:0002027Abdominal pain
HP:0002059Cerebral atrophy
HP:0003137Prolinuria
HP:0004387Enterocolitis
HP:0005490Postnatal macrocephaly
HP:0008672Calcium oxalate nephrolithiasis
HP:0008872Feeding difficulties in infancy
HP:0008947Floppy infant
HP:0040142Reduced circulating 5-oxoprolinase activity
HP:0410132Increased level of L-pyroglutamic acid in urine

GWAS associations

8 associations (top):

StudyTraitp-value
GCST001217_16Metabolic traits2.000000e-59
GCST006249_14Serum metabolite levels8.000000e-51
GCST008103_86Bipolar disorder1.000000e-06
GCST008115_8Bipolar I disorder2.000000e-08
GCST012020_19Serum metabolite levels6.000000e-58
GCST012020_402Serum metabolite levels4.000000e-100
GCST012353_35Serum metabolite concentrations in chronic kidney disease2.000000e-22
GCST90002397_670Mean spheric corpuscular volume1.000000e-31

EFO canonical traits (2, from GWAS)

EFO IDTrait name
EFO:0004725metabolite measurement
EFO:0009963bipolar I disorder

MeSH disease descriptors (2)

DescriptorNameTree numbers
C5353225-oxoprolinase deficiency (supp.)
C579932Autosomal Dominant Nocturnal Frontal Lobe Epilepsy (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

41 total (human), top 30 by PubMed support.

ChemicalActions (top 5)PubMed papers
sodium arsenitedecreases expression, increases expression3
Benzo(a)pyrenedecreases expression, increases methylation3
bisphenol Aaffects expression, affects cotreatment, increases methylation2
Phenylmercuric Acetateaffects cotreatment, decreases expression2
Valproic Acidaffects expression, decreases expression, increases methylation2
Aflatoxin B1affects expression, decreases expression2
p-Chloromercuribenzoic Aciddecreases expression, affects cotreatment2
aristolochic acid Idecreases expression1
afuresertibincreases expression1
FR900359increases phosphorylation1
bisphenol Fincreases expression1
bismuth tripotassium dicitratedecreases expression1
triphenyl phosphateaffects expression1
sulforaphanedecreases expression1
tris(1,3-dichloro-2-propyl)phosphateincreases expression1
perfluorooctanoic acidincreases expression1
mercuric bromideaffects cotreatment, decreases expression1
di-n-butylphosphoric acidaffects expression1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamideaffects cotreatment, decreases expression1
erucylphospho-N,N,N-trimethylpropylammoniumincreases expression1
belinostataffects cotreatment, decreases expression1
ICG 001increases expression1
bisphenol Bincreases expression1
abrinedecreases expression1
dorsomorphindecreases expression, affects cotreatment1
bisphenol Sincreases expression1
jinfukangincreases expression, affects cotreatment1
Resveratrolaffects cotreatment, decreases expression1
Temozolomideincreases expression1
Sunitinibincreases expression1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 75

This page pulls from 75 datasets indexed by BioBTree:

alphafoldalphamissenseantibodybgeebgee_evidencebindingdbbiogrid_interactionbrendabrenda_kineticsccdscellosauruschembl_activitychembl_targetciviccivic_evidenceclingen_dosageclingen_gene_validityclinical_trialsclinvarcollectrictd_gene_interactiondbsnpdepmapdiamond_similarityefoensemblentrezesm2_similarityexonfantom5_genefantom5_promotergenccgenerifgogoparentgtopdbgwasgwas_studyhgnchpointactinterprointogenjasparmeshmimmirdbmondomsigdborphanetorthologparalogpdbpfampharmgkb_clinicalpharmgkb_genepharmgkb_guidelinepharmgkb_variantpubchempubchem_activitypubchem_assaypubmedreactomereactomeparentrefseqrhearnacentralscxa_expressionscxa_gene_experimentsignorspliceaistring_interactiontranscriptufeatureuniprot